6-K - NeuroSense Therapeutics Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NeuroSense Therapeutics Ltd. announced a Special Meeting of Shareholders on March 10, 2026, to approve an amendment to its Articles of Association increasing registered share capital from 90 million to 200 million ordinary shares. The Board recommends approval to provide flexibility for strategic financing and advancement of PrimeC, including Phase 3 activities.

Key Takeaways

1Special Meeting scheduled for 4:00 p.m. Israel time on March 10, 2026 at 11 Hamenofim St., Building B, Herzliya 4672562, Israel

2Record date: February 17, 2026

3Proposal: Amend Articles to increase registered share capital to 200 million ordinary shares, no par value

4Current registered share capital: 90 million ordinary shares

5As of February 11, 2026: 33,396,608 ordinary shares issued and outstanding; ~39 million available for future issuance

6Board unanimously recommends voting FOR the proposal

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (3)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

NOTICE AND PROXY STATEMENT FOR THE SPECIAL MEETING OF SHAREHOLDERS OF THE REGISTRANT SCHEDULED FOR MARCH 10, 2026

99.2

PROXY CARD